BioCentury
ARTICLE | Clinical News

Fluticasone furoate/umeclidinium/vilanterol: Phase III data

June 27, 2016 7:00 AM UTC

Top-line data from the double-blind, double-dummy, international Phase III FULFIL trial in 1,810 COPD patients showed that once-daily inhaled fluticasone furoate/umeclidinium/vilanterol delivered in GlaxoSmithKline’s Ellipta dry powder inhaler met the co-primary endpoints of improving trough FEV1 (improvement of 171 mL, p<0.001) and SGRQ-C total score (reduction of 2.2 units, p<0.001) from baseline to week 24 vs. twice-daily Symbicort Turbohaler budesonide/formoterol. Fluticasone furoate/umeclidinium/vilanterol also led to a >=4-unit improvement in SGRQ-C total score in 50% of patients vs. 41% of patients receiving Symbicort Turbohaler. ...